Michael W Cannon
Overview
Explore the profile of Michael W Cannon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choucair K, Page S, Mattar B, Dakhil C, Nabbout N, Deutsch J, et al.
Clin Breast Cancer
. 2022 Dec;
23(2):155-161.
PMID: 36566135
Background: RNA-based genomic risk assessment estimates chemotherapy benefit in patients with hormone-receptor positive (HR+)/Human Epidermal Growth Factor 2-negative (ERBB2-) breast cancer (BC). It is virtually used in all patients with...
2.
Choucair K, Mattar B, Van Truong Q, Koeneke T, Van Truong P, Dakhil C, et al.
Oncologist
. 2022 Mar;
27(3):183-190.
PMID: 35274713
Background: Liquid biopsy testing offers a significant potential in selecting signal-matched therapies for advanced solid malignancies. The feasibility of liquid biopsy testing in a community-based oncology practice, and its actual...
3.
Micallef I, Maurer M, Wiseman G, Nikcevich D, Kurtin P, Cannon M, et al.
Blood
. 2011 Jun;
118(15):4053-61.
PMID: 21673350
Approximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal...
4.
Mc Kean H, Stella P, Hillman S, Rowland K, Cannon M, Behrens R, et al.
Cancer Invest
. 2011 Feb;
29(4):266-71.
PMID: 21345074
How do oncologists choose therapy for the elderly? Oncologists assigned patients aged 65 years or older with incurable non-small cell lung cancer to: (a) carboplatin (AUC = 2) + paclitaxel...
5.
Burch P, Mailliard J, Hillman D, Perez E, Krook J, Rowland K, et al.
Am J Clin Oncol
. 2005 Apr;
28(2):195-200.
PMID: 15803016
Background: This 2-stage, phase II cooperative group trial examined the efficacy and toxicity of 1000 mg/m2 gemcitabine plus 25 mg/m2 cisplatin weekly for 3 weeks and repeated every 28 days...
6.
Jatoi A, Stella P, Hillman S, Mailliard J, Vanone S, Perez E, et al.
Am J Clin Oncol
. 2003 Oct;
26(5):441-7.
PMID: 14528068
The purpose of this study was to determine the tumor response rate and toxicity profile of low-dose weekly carboplatin and paclitaxel in advanced non-small-cell lung cancer (SCLC) patients 65 or...
7.
Jatoi A, Hillman S, Stella P, Mailliard J, Sloan J, Vanone S, et al.
Support Care Cancer
. 2003 Sep;
11(7):460-4.
PMID: 14505160
Background: Performance scores predict benefits and toxicities from chemotherapy. Among older cancer patients, however, many investigators have empirically called for a detailed assessment of activities of daily living, claiming that...